Guidant 's Ancure
This article was originally published in The Gray Sheet
Executive Summary
Abdominal aortic anuerysm endovascular graft is recalled from existing hospital inventories and production halted by the company due to deficiencies in regulatory processes associated with deployment of the device and communications with the FDA, company reports March 16. The recall leaves Medtronic's AneuRx as the only AAA stent graft currently available on the U.S. market. Both firms have encountered problems in the past related to deployment of AAA devices. In November 1999, Guidant conducted a Class II recall of 287 Ancure units after a failure in the manufactuing process caused problems in the deployment of the product's attachment system
You may also be interested in...
UK Medical Devices Agency Issues AAA, Breast Implant Device Updates
Endovascualar prosthesis treatment outcomes remain contingent on factors such as aneurysmal remodeling and patients' vascular anatomy, the UK's Medical Devices Agency concludes in a 1May update on devices for abdominal and thoracic aortic aneurysms
UK Medical Devices Agency Issues AAA, Breast Implant Device Updates
Endovascualar prosthesis treatment outcomes remain contingent on factors such as aneurysmal remodeling and patients' vascular anatomy, the UK's Medical Devices Agency concludes in a 1May update on devices for abdominal and thoracic aortic aneurysms
Guidant Ancure
AAA endovascular graft will return to the U.S. market this quarter, following FDA approval of a PMA supplement allowing the company to proceed with full market release, company announces Aug. 17. Guidant President and CEO Ronald Dollens says he expects the abdominal aortic aneurysm repair device to realize previous sales levels "within one to two quarters" of launch. The Ancure underwent a worldwide recall on March 16 following reports of deployment problems with the minimally invasive system (1"The Gray Sheet" March 19, 2001, p. 24)